| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
The Trade: Broad Street Realty, Inc. (OTC:BRST) Director Samuel M Spiritos acquired a total of 10885 shares at an average price of $2.28. To acquire these shares, it cost $24,831.65.
What’s Happening: The company’s stock surged over 30% over the previous month.
What Broad Street Realty Does: Broad Street Realty Inc is a fully integrated real estate company that owns, operates, develops, and redevelops primarily grocery-anchored shopping centers and street retail-based properties in the Mid-Atlantic and Denver, Colorado markets.
The Trade: Baudax Bio, Inc. (NASDAQ:BXRX) Director Winston Churchill acquired a total of 100000 shares shares at an average price of $0.63. The insider spent $62,930.00 to buy those shares.
What’s Happening: The company, last month, reported downbeat quarterly results.
What Baudax Bio Does: Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings.
The Trade: Calyxt, Inc. (NASDAQ:CLXT) President and CEO Michael A Carr acquired a total of 10000 shares at an average price of $3.98. To acquire these shares, it cost $39,776.00.
What’s Happening: Calyxt, last month, reported better-than-expected quarterly results.
What Calyxt Does: Calyxt Inc is a technology company focused on delivering plant-based innovations and solutions.
The Trade: ReShape Lifesciences Inc. (NASDAQ:RSLS) Chief Financial Officer Thomas Stankovich acquired a total of 15000 shares at an average price of $3.43. To acquire these shares, it cost $51,435.00.
What’s Happening: The company recently reported Q2revenue of $3.5 million, up from $1.7 million in the year-ago period.
What ReShape Lifesciences Does: Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases.
The Trade: Amplify Energy Corp. (NYSE:AMPY) Director Evan Lederman acquired a total of 10000 shares at an average price of $3.69. To acquire these shares, it cost $36,900.00.
What’s Happening: The company, last month, reported a narrower quarterly loss.
What Amplify Energy Does: Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation and production of oil and natural gas properties in the United States.
